Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation

Karin B. Nelson, Judith K. Grether, Lisa A. Croen, James M. Dambrosia, Benjamin F. Dickens, Laura L. Jelliffe, Robin L Hansen, Terry M. Phillips

Research output: Contribution to journalArticle

337 Citations (Scopus)

Abstract

There has been little exploration of major biologic regulators of cerebral development in autism. In archived neonatal blood of children with autistic spectrum disorders (n = 69), mental retardation without autism (n = 60), or cerebral palsy (CP, n = 63) and of control children (n = 54), we used recycling immunoaffinity chromatography to measure the neuropeptides substance P (SP), vasoactive intestinal peptide (VIP), pituitary adenylate cyclase-activating polypeptide (PACAP), calcitonin gene-related peptide (CGRP), and the neurotrophins nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin 3 (NT3), and neurotrophin 4/5 (NT4/5). Neonatal concentrations of VIP, CGRP, BDNF, and NT4/5 were higher (ANOVA, all p values < 0.0001 by Scheffe test for pairwise differences) in children in the autistic spectrum and in those with mental retardation without autism than in control children. In 99% of children with autism and 97% with mental retardation, levels of at least one of these substances exceeded those of all control children. Concentrations were similar in subgroups of the autistic spectrum (core syndrome with or without mental retardation, other autistic spectrum disorders with or without mental retardation) and in the presence or absence of a history of regression. Among children with mental retardation, concentrations did not differ by severity or known cause (n = 11, including 4 with Down syndrome). Concentrations of measured substances were similar in children with CP as compared with control subjects. SP, PACAP, NGF, and NT3 were not different by diagnostic group. No measured analyte distinguished children with autism from children with mental retardation alone. In autism and in a heterogeneous group of disorders of cognitive function, overexpression of certain neuropeptides and neurotrophins was observed in peripheral blood drawn in the first days of life.

Original languageEnglish (US)
Pages (from-to)597-606
Number of pages10
JournalAnnals of Neurology
Volume49
Issue number5
DOIs
StatePublished - 2001

Fingerprint

Nerve Growth Factors
Autistic Disorder
Neuropeptides
Intellectual Disability
Neurotrophin 3
Pituitary Adenylate Cyclase-Activating Polypeptide
Calcitonin Gene-Related Peptide
Vasoactive Intestinal Peptide
Brain-Derived Neurotrophic Factor
Nerve Growth Factor
Substance P
Recycling
Cerebral Palsy
Down Syndrome
Cognition
Chromatography
Analysis of Variance

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Nelson, K. B., Grether, J. K., Croen, L. A., Dambrosia, J. M., Dickens, B. F., Jelliffe, L. L., ... Phillips, T. M. (2001). Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation. Annals of Neurology, 49(5), 597-606. https://doi.org/10.1002/ana.1024

Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation. / Nelson, Karin B.; Grether, Judith K.; Croen, Lisa A.; Dambrosia, James M.; Dickens, Benjamin F.; Jelliffe, Laura L.; Hansen, Robin L; Phillips, Terry M.

In: Annals of Neurology, Vol. 49, No. 5, 2001, p. 597-606.

Research output: Contribution to journalArticle

Nelson, KB, Grether, JK, Croen, LA, Dambrosia, JM, Dickens, BF, Jelliffe, LL, Hansen, RL & Phillips, TM 2001, 'Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation', Annals of Neurology, vol. 49, no. 5, pp. 597-606. https://doi.org/10.1002/ana.1024
Nelson KB, Grether JK, Croen LA, Dambrosia JM, Dickens BF, Jelliffe LL et al. Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation. Annals of Neurology. 2001;49(5):597-606. https://doi.org/10.1002/ana.1024
Nelson, Karin B. ; Grether, Judith K. ; Croen, Lisa A. ; Dambrosia, James M. ; Dickens, Benjamin F. ; Jelliffe, Laura L. ; Hansen, Robin L ; Phillips, Terry M. / Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation. In: Annals of Neurology. 2001 ; Vol. 49, No. 5. pp. 597-606.
@article{0b453010dda346efb2c8078da128db16,
title = "Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation",
abstract = "There has been little exploration of major biologic regulators of cerebral development in autism. In archived neonatal blood of children with autistic spectrum disorders (n = 69), mental retardation without autism (n = 60), or cerebral palsy (CP, n = 63) and of control children (n = 54), we used recycling immunoaffinity chromatography to measure the neuropeptides substance P (SP), vasoactive intestinal peptide (VIP), pituitary adenylate cyclase-activating polypeptide (PACAP), calcitonin gene-related peptide (CGRP), and the neurotrophins nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin 3 (NT3), and neurotrophin 4/5 (NT4/5). Neonatal concentrations of VIP, CGRP, BDNF, and NT4/5 were higher (ANOVA, all p values < 0.0001 by Scheffe test for pairwise differences) in children in the autistic spectrum and in those with mental retardation without autism than in control children. In 99{\%} of children with autism and 97{\%} with mental retardation, levels of at least one of these substances exceeded those of all control children. Concentrations were similar in subgroups of the autistic spectrum (core syndrome with or without mental retardation, other autistic spectrum disorders with or without mental retardation) and in the presence or absence of a history of regression. Among children with mental retardation, concentrations did not differ by severity or known cause (n = 11, including 4 with Down syndrome). Concentrations of measured substances were similar in children with CP as compared with control subjects. SP, PACAP, NGF, and NT3 were not different by diagnostic group. No measured analyte distinguished children with autism from children with mental retardation alone. In autism and in a heterogeneous group of disorders of cognitive function, overexpression of certain neuropeptides and neurotrophins was observed in peripheral blood drawn in the first days of life.",
author = "Nelson, {Karin B.} and Grether, {Judith K.} and Croen, {Lisa A.} and Dambrosia, {James M.} and Dickens, {Benjamin F.} and Jelliffe, {Laura L.} and Hansen, {Robin L} and Phillips, {Terry M.}",
year = "2001",
doi = "10.1002/ana.1024",
language = "English (US)",
volume = "49",
pages = "597--606",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation

AU - Nelson, Karin B.

AU - Grether, Judith K.

AU - Croen, Lisa A.

AU - Dambrosia, James M.

AU - Dickens, Benjamin F.

AU - Jelliffe, Laura L.

AU - Hansen, Robin L

AU - Phillips, Terry M.

PY - 2001

Y1 - 2001

N2 - There has been little exploration of major biologic regulators of cerebral development in autism. In archived neonatal blood of children with autistic spectrum disorders (n = 69), mental retardation without autism (n = 60), or cerebral palsy (CP, n = 63) and of control children (n = 54), we used recycling immunoaffinity chromatography to measure the neuropeptides substance P (SP), vasoactive intestinal peptide (VIP), pituitary adenylate cyclase-activating polypeptide (PACAP), calcitonin gene-related peptide (CGRP), and the neurotrophins nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin 3 (NT3), and neurotrophin 4/5 (NT4/5). Neonatal concentrations of VIP, CGRP, BDNF, and NT4/5 were higher (ANOVA, all p values < 0.0001 by Scheffe test for pairwise differences) in children in the autistic spectrum and in those with mental retardation without autism than in control children. In 99% of children with autism and 97% with mental retardation, levels of at least one of these substances exceeded those of all control children. Concentrations were similar in subgroups of the autistic spectrum (core syndrome with or without mental retardation, other autistic spectrum disorders with or without mental retardation) and in the presence or absence of a history of regression. Among children with mental retardation, concentrations did not differ by severity or known cause (n = 11, including 4 with Down syndrome). Concentrations of measured substances were similar in children with CP as compared with control subjects. SP, PACAP, NGF, and NT3 were not different by diagnostic group. No measured analyte distinguished children with autism from children with mental retardation alone. In autism and in a heterogeneous group of disorders of cognitive function, overexpression of certain neuropeptides and neurotrophins was observed in peripheral blood drawn in the first days of life.

AB - There has been little exploration of major biologic regulators of cerebral development in autism. In archived neonatal blood of children with autistic spectrum disorders (n = 69), mental retardation without autism (n = 60), or cerebral palsy (CP, n = 63) and of control children (n = 54), we used recycling immunoaffinity chromatography to measure the neuropeptides substance P (SP), vasoactive intestinal peptide (VIP), pituitary adenylate cyclase-activating polypeptide (PACAP), calcitonin gene-related peptide (CGRP), and the neurotrophins nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin 3 (NT3), and neurotrophin 4/5 (NT4/5). Neonatal concentrations of VIP, CGRP, BDNF, and NT4/5 were higher (ANOVA, all p values < 0.0001 by Scheffe test for pairwise differences) in children in the autistic spectrum and in those with mental retardation without autism than in control children. In 99% of children with autism and 97% with mental retardation, levels of at least one of these substances exceeded those of all control children. Concentrations were similar in subgroups of the autistic spectrum (core syndrome with or without mental retardation, other autistic spectrum disorders with or without mental retardation) and in the presence or absence of a history of regression. Among children with mental retardation, concentrations did not differ by severity or known cause (n = 11, including 4 with Down syndrome). Concentrations of measured substances were similar in children with CP as compared with control subjects. SP, PACAP, NGF, and NT3 were not different by diagnostic group. No measured analyte distinguished children with autism from children with mental retardation alone. In autism and in a heterogeneous group of disorders of cognitive function, overexpression of certain neuropeptides and neurotrophins was observed in peripheral blood drawn in the first days of life.

UR - http://www.scopus.com/inward/record.url?scp=0035021249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035021249&partnerID=8YFLogxK

U2 - 10.1002/ana.1024

DO - 10.1002/ana.1024

M3 - Article

VL - 49

SP - 597

EP - 606

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 5

ER -